Radiology:对于那些复发小肝癌如何是好呢?

2018-08-24 shaosai MedSci原创

本研究旨在评价经皮US/MRI联合引导下射频消融(RFA)术对复发性亚厘米肝细胞肝癌(HCCs)的治疗可行性及预后结果,将结果发表在Radiology上。

本研究旨在评价经皮US/MRI联合引导下射频消融(RFA)术对复发性亚厘米肝细胞肝癌(HCCs)的治疗可行性及预后结果,将结果发表在Radiology上。

本研究共纳入了194例预行US检查的复发性亚厘米HCCs患者,其中有186例行US检查。复发性HCCs定义为具有MRI典型表现的高强化结节(>5.5 mm且<10 mm)。本研究旨在评价行US检查后何时行US/MRI联合引导下经皮RFA具有技术可行性及RFA的治疗效果(包括技术上成功率、技术效率和局部肿瘤进展(LTP)和主要并发症)。利用Kaplan-Meier法评价累及LTP率。

结果为,经皮RFA在预行US检查的患者的可行性率为65.7% (138 of 210 HCCs)。RFA可行性受限的最主要原因为标记肿瘤在US显示欠清。在138处RFA可行的亚厘米HCCs中,125处病变行经皮RFA。技术上成功和技术上有效的比例为98.4% (123 of 125)。在1/2/3年LTP增长率分别为3.6%、5.4%、7.4%。主要并发症发生率为2.5% (three of 119)。

本研究表明,经皮US/MRI联合引导下RFA是一种治疗亚厘米复发性肝癌可行有效的治疗方法。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069727, encodeId=9a3e2069e27cb, content=<a href='/topic/show?id=e72e4e09945' target=_blank style='color:#2F92EE;'>#小肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47099, encryptionId=e72e4e09945, topicName=小肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Thu Jan 24 11:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340672, encodeId=29093406e299, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 25 07:59:59 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340597, encodeId=b7c034059ed3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Aug 24 21:06:09 CST 2018, time=2018-08-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2069727, encodeId=9a3e2069e27cb, content=<a href='/topic/show?id=e72e4e09945' target=_blank style='color:#2F92EE;'>#小肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47099, encryptionId=e72e4e09945, topicName=小肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Thu Jan 24 11:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340672, encodeId=29093406e299, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 25 07:59:59 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340597, encodeId=b7c034059ed3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Aug 24 21:06:09 CST 2018, time=2018-08-24, status=1, ipAttribution=)]
    2018-08-25 kafei

    了解一下谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2069727, encodeId=9a3e2069e27cb, content=<a href='/topic/show?id=e72e4e09945' target=_blank style='color:#2F92EE;'>#小肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47099, encryptionId=e72e4e09945, topicName=小肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Thu Jan 24 11:03:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340672, encodeId=29093406e299, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Aug 25 07:59:59 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340597, encodeId=b7c034059ed3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Aug 24 21:06:09 CST 2018, time=2018-08-24, status=1, ipAttribution=)]
    2018-08-24 医者仁心5538

    学习了

    0